Mitogen-activated protein kinase kinase kinase 12 (MAP3K12)
Target
MAP3K12
Molecular classification
Enzyme (Protein kinase), Serine/threonine protein kinase, Member of the mitogen-activated protein kinase kinase kinase family (MAP3K), LZK subfamily
01
Overview
Mitogen-activated protein kinase kinase kinase 12 (MAP3K12), also known as Dual leucine zipper kinase (DLK), is a serine/threonine-protein kinase predominantly expressed in neurons. It is a critical upstream regulator of kinase cascades that mediate responses to cellular stress, axonal injury, and neuronal development. MAP3K12 activates the MAPK/JNK pathway by phosphorylating and activating MKK7, leading to downstream activation of c-Jun and other transcription factors, ultimately regulating processes such as axon growth, neuronal migration, apoptosis, and axonal degeneration. DLK plays key roles in nervous system development, injury responses, neurodegeneration, and regeneration, and is considered an emerging therapeutic target for neurodegenerative disorders. Selective inhibition of MAP3K12/DLK is neuroprotective in experimental models, but safety concerns remain due to its roles in normal neuronal function and development.
Inhibition of MAP3K12/DLK reduces phosphorylation of MKK7 and JNK, blocking pro-apoptotic and degenerative signaling in neurons, thereby providing neuroprotection
03
Biological functions
Signal transductionRegulation of neuronal differentiationNeuronal development (axon growth, neuronal migration)Apoptosis (programmed cell death)Axonal injury response/regenerationActivation of JNK (c-Jun N-terminal kinase) pathwayStress response in neurons
MAP3K12/DLK is essential for neuronal development and regenerative responses, suggesting that broad inhibition could potentially disrupt neuronal plasticity or developmentPossible off-target effects or interference with adaptive neuronal stress responses
06
Interacting drugs
No specific FDA-approved drugs listed; several small-molecule inhibitors are under investigation preclinically as neuroprotective agents targeting DLK/MAP3K12 in neurodegenerative disease contexts
07
Biomarkers
Phosphorylation status of JNK, c-Jun, and related MAPK pathway proteins may be used as biomarkers in research settings; no validated clinical biomarkers for this target currently
Beyond the preview
Go deeper on Mitogen-activated protein kinase kinase kinase 12 (MAP3K12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 12 (MAP3K12).